JP7050335B2 - 骨形成不全症の処置における抗スクレロスチン抗体の使用 - Google Patents

骨形成不全症の処置における抗スクレロスチン抗体の使用 Download PDF

Info

Publication number
JP7050335B2
JP7050335B2 JP2019533586A JP2019533586A JP7050335B2 JP 7050335 B2 JP7050335 B2 JP 7050335B2 JP 2019533586 A JP2019533586 A JP 2019533586A JP 2019533586 A JP2019533586 A JP 2019533586A JP 7050335 B2 JP7050335 B2 JP 7050335B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sclerostin antibody
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502219A5 (enExample
JP2020502219A (ja
Inventor
ユンカー，ウヴェ
クナイセル，ミカエラ
ケント ハル，アントニー
ジョイ ユディ，レナ
マニング リグス，マシュー
Original Assignee
メレオ バイオファーマ ３ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メレオ バイオファーマ ３ リミテッド filed Critical メレオ バイオファーマ ３ リミテッド
Publication of JP2020502219A publication Critical patent/JP2020502219A/ja
Publication of JP2020502219A5 publication Critical patent/JP2020502219A5/ja
Priority to JP2021200994A priority Critical patent/JP2022046529A/ja
Application granted granted Critical
Publication of JP7050335B2 publication Critical patent/JP7050335B2/ja
Priority to JP2024179475A priority patent/JP2025020150A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019533586A 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用 Active JP7050335B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021200994A JP2022046529A (ja) 2016-12-21 2021-12-10 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP2024179475A JP2025020150A (ja) 2016-12-21 2024-10-11 骨形成不全症の処置における抗スクレロスチン抗体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437353P 2016-12-21 2016-12-21
US62/437,353 2016-12-21
PCT/GB2017/053850 WO2018115880A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021200994A Division JP2022046529A (ja) 2016-12-21 2021-12-10 骨形成不全症の処置における抗スクレロスチン抗体の使用

Publications (3)

Publication Number Publication Date
JP2020502219A JP2020502219A (ja) 2020-01-23
JP2020502219A5 JP2020502219A5 (enExample) 2021-02-04
JP7050335B2 true JP7050335B2 (ja) 2022-04-08

Family

ID=60915566

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533586A Active JP7050335B2 (ja) 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP2021200994A Pending JP2022046529A (ja) 2016-12-21 2021-12-10 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP2024179475A Pending JP2025020150A (ja) 2016-12-21 2024-10-11 骨形成不全症の処置における抗スクレロスチン抗体の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021200994A Pending JP2022046529A (ja) 2016-12-21 2021-12-10 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP2024179475A Pending JP2025020150A (ja) 2016-12-21 2024-10-11 骨形成不全症の処置における抗スクレロスチン抗体の使用

Country Status (23)

Country Link
US (5) US20200179509A1 (enExample)
EP (2) EP3868780A1 (enExample)
JP (3) JP7050335B2 (enExample)
KR (3) KR20240113615A (enExample)
CN (2) CN117442720A (enExample)
AU (1) AU2017381433B2 (enExample)
BR (1) BR112019012731A2 (enExample)
CA (1) CA3047221A1 (enExample)
CL (1) CL2019001749A1 (enExample)
CY (1) CY1124238T1 (enExample)
DK (1) DK3478719T6 (enExample)
ES (1) ES2862922T7 (enExample)
FI (1) FI3478719T6 (enExample)
HR (1) HRP20210207T4 (enExample)
HU (1) HUE053436T2 (enExample)
IL (1) IL267430B1 (enExample)
LT (1) LT3478719T (enExample)
MX (1) MX2019007161A (enExample)
NZ (1) NZ754676A (enExample)
PL (1) PL3478719T6 (enExample)
PT (1) PT3478719T (enExample)
SI (1) SI3478719T2 (enExample)
WO (1) WO2018115880A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046529A (ja) * 2016-12-21 2022-03-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN112166120B (zh) 2018-03-30 2024-09-10 安姆根有限公司 C末端抗体变体
EP3807266B1 (en) 2018-06-18 2023-10-25 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
AU2022357544A1 (en) * 2021-09-30 2024-04-11 Mereo Biopharma 3 Limited Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121170A (ja) 2007-10-12 2016-07-07 メレオ バイオファーマ ３ リミテッド スクレロスチンに対する抗体の使用のための組成物および方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
UA96474C2 (en) * 2007-03-20 2011-11-10 Эли Лилли Энд Компани Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
EP2558106A1 (en) * 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AU2017381433B2 (en) * 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2020502218A (ja) * 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121170A (ja) 2007-10-12 2016-07-07 メレオ バイオファーマ ３ リミテッド スクレロスチンに対する抗体の使用のための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Bone and Mineral Research，2016年05月，Vol. 31, No. 5，p.1030-1040

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046529A (ja) * 2016-12-21 2022-03-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用

Also Published As

Publication number Publication date
CL2019001749A1 (es) 2019-12-27
CA3047221A1 (en) 2018-06-28
US20230365669A1 (en) 2023-11-16
DK3478719T6 (da) 2025-01-20
US20210253684A1 (en) 2021-08-19
EP3868780A1 (en) 2021-08-25
CN110325548B (zh) 2023-11-17
RU2019118719A (ru) 2021-01-22
HUE053436T2 (hu) 2021-06-28
ES2862922T7 (en) 2025-02-26
JP2025020150A (ja) 2025-02-12
US20200179509A1 (en) 2020-06-11
ES2862922T3 (es) 2021-10-08
US20240400666A1 (en) 2024-12-05
WO2018115880A1 (en) 2018-06-28
RU2019118719A3 (enExample) 2021-06-01
SI3478719T1 (sl) 2021-09-30
IL267430A (en) 2019-08-29
SI3478719T2 (sl) 2025-07-31
EP3478719B1 (en) 2021-01-20
CN117442720A (zh) 2024-01-26
IL267430B1 (en) 2025-09-01
DK3478719T3 (da) 2021-03-01
US20200123242A1 (en) 2020-04-23
MX2019007161A (es) 2020-02-12
FI3478719T6 (fi) 2025-01-20
LT3478719T (lt) 2021-04-12
KR20220051269A (ko) 2022-04-26
EP3478719A1 (en) 2019-05-08
JP2020502219A (ja) 2020-01-23
KR20240113615A (ko) 2024-07-22
CN110325548A (zh) 2019-10-11
PL3478719T6 (pl) 2025-01-27
BR112019012731A2 (pt) 2019-11-26
EP3478719B3 (en) 2024-12-18
AU2017381433A1 (en) 2019-07-04
KR20190096409A (ko) 2019-08-19
AU2017381433B2 (en) 2024-11-14
CY1124238T1 (el) 2022-07-22
JP2022046529A (ja) 2022-03-23
HRP20210207T4 (hr) 2025-01-31
PL3478719T3 (pl) 2021-10-25
HRP20210207T1 (hr) 2021-03-19
PT3478719T (pt) 2021-03-18
NZ754676A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
JP7050335B2 (ja) 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
KR101620771B1 (ko) Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
JP6845012B2 (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US20250122273A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
HK40058082A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021B (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201216

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211210

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220128

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7050335

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250